Evaluation of the Human Papillomavirus mRNA Test for the detection of cervical lesions in Japan

Aims. For the screening of cervical abnormalities, human papillomavirus (HPV) DNA testing is widely used along with Papanicolaou (Pap) testing. Although the sensitivity of the HPV DNA testing is good, its specificity is relatively low. In the present study, the authors evaluated the use of the Gen-Probe APTIMA HPV Assay for the detection of HPV mRNA and compared it with HPV DNA testing. Materials and Methods. Liquid cervical Pap specimens collected from 410 women were assessed using the APTIMA test, the Qiagen Hybrid Capture 2 HPV DNA (HC2) Test, and the AMPLICOR HPV Test. Results. The sensitivity and specificity for the detection of high-risk HPV were 85.6% and 99.2% for the APTIMA test, 94.1% and 98.4% for the HC2 test, and 90.2% and 95.7% for the AMPLICOR test, respectively. As the severity of the cervical lesion progressed, the positive rate of the three tests indicated a similar increase. The clinical sensitivity and specificity for the detection of squamous intraepithelial lesion (SIL) were 91.2% and 84.2% for the APTIMA test, 94.5% and 80.4% for the HC2 test, and 87.9% and 78.2% for the AMPLICOR test, respectively. Conclusion. The APTIMA is sensitive and specific for the detection of high-risk HPV. In the specimens with SIL, the APTIMA test is more specific than the HC2 and the AMPLICOR tests. This indicates that the APTIMA test may improve patient management and reduce the cost of screening.

Cytology; Human papillomavirus; mRNA; Specificity; Squamous intraepithelial lesion.

[1] Kjaer S.K., van den Brule A.J., Paull G., Svare E.I., Sherman M.E., Thomsen B.L., et al.: “Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study”. BMJ, 2002, 325, 572.

[2] zur Hausen H.: “Human papillomaviruses in the pathogenesis of anogenital cancer”. Virology, 1991, 184, 9.

[3] Plummer M., Schiffman M., Castle P.E., Maucort-Boulch D., Wheeler C.M.: “A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion”. J. Infect. Dis., 2007, 195, 1582.

[4] Doorbar J.: “Molecular biology of human papillomavirus infection and cervical cancer”. Clin. Sci. (Lond.), 2006, 110, 525.

[5] zur Hausen H.: “Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes”. Semin. Cancer Biol., 1999, 9, 405.

[6] Kulasingam S.L., Hughes J.P., Kiviat N.B., Mao C., Weiss N.S., Kuypers J.M., et al.: “Evaluation of human papillomavirus testing i primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral”. JAMA, 2002, 288, 1749.

[7] Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al.: “Overview of the European and North American studies on HPV testing in primary cervical cancer screening”. Int. J. Cancer, 2006, 119, 1095.

[8] Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al.: “Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer”. N. Engl. J. Med., 2007, 357, 1579.

[9] van Rosmalen J., de Kok I.M., van Ballegooijen M.: “Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing”. BJOG, 2012, 119, 699.

[10] Arbyn M., Martin-Hirsch P., Buntinx F., Van Ranst M., Paraskevaidis E., Dillner J.: “Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate”. J. Cell. Mol. Med., 2009, 13, 648.

[11] Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S.: “Human papillomavirus and cervical cancer”. Lancet, 2007, 370, 890.

[12] Burger E.A., Kornor H., Klemp M., Lauvrak V., Kristiansen I.S.: “HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review”. Gynecol. Oncol., 2011, 120, 430.

[13] Szarewski A., Ambroisine L., Cadman L., Austin J., Ho L., Terry G., et al.: “Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears”. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 3033.

[14] Wu R., Belinson S.E., Du H., Na W., Qu X., Wu R., et al.: “Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I”. Int. J. Gynecol. Cancer, 2010, 20, 1411.

[15] Dockter J., Schroder A., Hill C., Guzenski L., Monsonego J., Giachetti C.: “Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions”. J. Clin. Virol., 2009, 45, S55.

[16] Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., Ghissassi F.: “Carcinogenicity of human papillomaviruses”. Lancet Oncol., 2005, 6, 204.

[17] Castle P.E., Solomon D., Wheeler C.M., Gravitt P.E., Wacholder S., Schiffman M.: “Human papillomavirus genotype specificity of hybrid capture 2”. J. Clin. Microbiol., 2008, 46, 2595.

[18] Murphy P.G., Henderson D.T., Adams M.D., Horlick E.A., Dixon E.P., King L.M., et al.: “Isolation of RNA from cell lines and cervical cytology specimens stored in BD SurePath preservative fluid and downstream detection of housekeeping gene and HPV E6 expression using real time RT-PCR”. J. Virol. Methods, 2009, 156, 138.

[19] Waldstrom M., Ornskov D.: “Clinical performance of a human papillomavirus messenger RNA test (Aptima HPV Assay) on residual material from archived 3-year-old PreservCyt samples with low-grade squamous intraepithelial lesion”. Arch. Pathol. Lab. Med., 2011, 135, 1052.

[20] Coquillard G., Palao B., Patterson B.K.: “Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA”. Gynecol. Oncol., 2011, 120, 89.

[21] Ovestad I.T., Vennestrom U., Andersen L., Gudlaugsson E., Munk A.C., Malpica A., et al.: “Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3”. Gynecol. Oncol., 2011, 123, 278.

[22] Reuschenbach M., Clad A., von Knebel Doeberitz C., Wentzensen N, Rahmsdorf J., Schaffrath F., et al.: “Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results”. Gynecol. Oncol., 2010, 119, 98.

[23] Sotlar K., Stubner A., Diemer D., Menton S., Menton M., Dietz K., et al.: “Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction”. J. Med. Virol., 2004, 74, 107.

[24] Lie A.K., Risberg B., Borge B., Sandstad B., Delabie J., Rimala R., et al.: “DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia”. Gynecol. Oncol., 2005, 97, 908.

[25] Cuschieri K.S., Whitley M.J., Cubie H.A.: “Human papillomavirus type specific DNA and RNA persistence—implications for cervical disease progression and monitoring”. J. Med. Virol., 2004, 73, 65.

[26] Sherman M.E., Lorincz A.T., Scott D.R., Wacholder S., Castle P.E, Glass A.G., et al.: “Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis”. J. Natl. Cancer Inst., 2003, 95, 46.